CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer
- Conditions
- Diabetic Neuropathic Foot Ulcers
- Interventions
- Biological: CHF6467 active
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 93
- Registration Number
- NCT04077671
- Locations
- 🇧🇬
Comac Medical Ltd., Sofia, Bulgaria
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
- Conditions
- Asthma; Eosinophilic
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 810
- Registration Number
- NCT04049175
- Locations
- 🇧🇬
Medical Center "Nov Rehabilitatsionen Tsentar" Ltd, Stara Zagora, Bulgaria
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 136
- Registration Number
- NCT04032535
- Locations
- 🇬🇧
Richmond Pharmacology, London, United Kingdom
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT04031066
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
- Conditions
- Cystic FibrosisNon-Cystic Fibrosis Bronchiectasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 68
- Registration Number
- NCT04010799
- Locations
- 🇩🇪
IKF Institut für klinische Forschung Pneumologie, Frankfurt/Main, Germany
Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT03992443
- Locations
- 🇧🇬
Chiesi Investigational site, Stara Zagora, Bulgaria
🇭🇺Chiesi investigational site, Székesfehérvár, Hungary
🇧🇬Chiesi Investigational Site, Razgrad, Bulgaria
Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence
- Conditions
- Asthma
- Interventions
- Behavioral: Marketed experience application on adherence
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 160
- Registration Number
- NCT03951714
- Locations
- 🇬🇧
Barlow Medical Centre, Manchester, United Kingdom
PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects
- Conditions
- Asthma
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment CDrug: Treatment E
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 30
- Registration Number
- NCT03942666
- Locations
- 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 750
- Registration Number
- NCT03888131
- Locations
- 🇨🇳
Site 15633 - Tianjin Haihe Hospital, Tianjin, Tianjin, China
🇨🇳Site 15642 - Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
🇨🇳Site 15639 -The second Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
Registry Study of Revcovi Treatment in Patients With ADA-SCID
- Conditions
- Adenosine Deaminase Severe Combined Immunodeficiency
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 32
- Registration Number
- NCT03878069
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States